The pharmaceutical giant raised its full-year guidance after third-quarter revenue and core earnings per share topped ...

We recently compiled a list of the 10 Best UK Stocks to Invest in Now. In this article, we are going to take a look at where ...

AstraZeneca's key medicines, mainly cancer drugs, Lynparza, Tagrisso and Imfinzi, and diabetes medicine Farxiga are expected ...

Leerink Partners analyst Andrew Berens has maintained their bullish stance on AZN stock, giving a Buy rating yesterday. Andrew Berens gave his rating based on several factors, including AstraZeneca’s ...

AstraZeneca's price plunge following a fraud investigation in China could be just the time to buy AZN stock as big picture ...

Additionally, AstraZeneca increased its guidance for the fiscal year ... In another report released today, Barclays also maintained a Buy rating on the stock with a £140.00 price target. TipRanks ...

AstraZeneca’s growth was driven by its portfolio of products in the oncology, biopharmaceuticals and rare disease segments ...

AstraZeneca beat third-quarter expectations and lifted its guidance Tuesday, but AstraZeneca stock slipped amid a criminal probe in China.

Chinese authorities detained AstraZeneca employees amid a probe into data privacy breaches and unlicensed drug sales, stock ...

AstraZeneca’s stock price dropped by 8.4% during Tuesday’s trading in London after a report fueled fears of a potentially ...

Four analysts surveyed by Zacks expected $13.04 billion. Astrazeneca shares have decreased nearly 4% since the beginning of the year. The stock has climbed 1% in the last 12 months.

BMO Capital Markets analyst Etzer Darout in a note to investors said the insurance fraud probe represents a “headline risk” ...